Literature DB >> 23804414

Hypoxic tumor microenvironment in advanced retinoblastoma.

Job Sudhakar1, Nalini Venkatesan, Shruthi Lakshmanan, Vikas Khetan, Subramanian Krishnakumar, Jyotirmay Biswas.   

Abstract

PURPOSE: Retinoblastoma (RB) is a malignant tumor of infancy and childhood. Unfavorable therapeutic response is still a quest in many tumors, including retinoblastoma. Hypoxic tumor microenvironment is one of the factors that determine the therapeutic response in many tumors. The purpose of this study was to determine the presence of hypoxia and its related proteins; Hypoxia inducible factor-1α (HIF-1α), Carbonic anhydrase IX (CA IX) and survivin in RB and their association with clinicopathological features.
MATERIALS AND METHODS: We evaluated the expression of HIF-1α and survivin by immunohistochemistry in 42 archival retinoblastoma tumors and CA IX; a hypoxia marker in 33 tumors in the same cohort. The expression was correlated with tumor groups based on invasion, differentiation and IIRC.
RESULTS: Expression of HIF-1α, survivin and CA IX was observed in 83% (35/42), 86% (36/42), and 93% (31/33) of tumors respectively. We observed no significance between HIF-1α and CA IX expression in tumors with invasion, differentiation and in IIRC tumor groups. An increased survivin expression was observed in group E tumors than in group D tumors (P = 0.044). A significant association was observed between HIF-1α and survivin in differentiated (r = -0.582; P = < 0.01) and undifferentiated tumors groups (r = 0.513; P = <0.012). A similar significant association was observed between HIF-1α and CA IX in tumors with high immunoreactivity for HIF-1α (r = 0.833; P = <0.01).
CONCLUSION: Based on these observations, we propose that HIF-1α pathway is deregulated in RB. The role of drug resistance and the potential of targeting HIF-1α, CA IX, and survivin in RB should further examined.
Copyright © 2013 Wiley Periodicals, Inc.

Entities:  

Keywords:  CA IX; HIF-1; chemoresistance; hypoxia; retinoblastoma; survivin

Mesh:

Substances:

Year:  2013        PMID: 23804414     DOI: 10.1002/pbc.24599

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  9 in total

1.  MicroRNA-320 regulates autophagy in retinoblastoma by targeting hypoxia inducible factor-1α.

Authors:  Yong Liang; Xi Chen; Zhu Liang
Journal:  Exp Ther Med       Date:  2017-07-11       Impact factor: 2.447

2.  Targeting Survivin Enhances Chemosensitivity in Retinoblastoma Cells and Orthotopic Tumors.

Authors:  Angela Ferrario; Marian Luna; Natalie Rucker; Sam Wong; Ariel Lederman; Jonathan Kim; Charles Gomer
Journal:  PLoS One       Date:  2016-04-06       Impact factor: 3.240

3.  Overexpression of pyruvate dehydrogenase kinase 1 in retinoblastoma: A potential therapeutic opportunity for targeting vitreous seeds and hypoxic regions.

Authors:  Swatishree Sradhanjali; Devjyoti Tripathy; Suryasnata Rath; Ruchi Mittal; Mamatha M Reddy
Journal:  PLoS One       Date:  2017-05-15       Impact factor: 3.240

4.  Retinoblastoma Is Characterized by a Cold, CD8+ Cell Poor, PD-L1- Microenvironment, Which Turns Into Hot, CD8+ Cell Rich, PD-L1+ After Chemotherapy.

Authors:  Clelia Miracco; Paolo Toti; Maria Chiara Gelmi; Sara Aversa; Gennaro Baldino; Paolo Galluzzi; Sonia De Francesco; Federica Petrelli; Ester Sorrentino; Giuseppe Belmonte; Daniela Galimberti; Sandra Bracco; Theodora Hadjistilianou
Journal:  Invest Ophthalmol Vis Sci       Date:  2021-02-01       Impact factor: 4.799

5.  RB1 loss triggers dependence on ESRRG in retinoblastoma.

Authors:  Matthew G Field; Jeffim N Kuznetsoff; Michelle G Zhang; James J Dollar; Michael A Durante; Yoseph Sayegh; Christina L Decatur; Stefan Kurtenbach; Daniel Pelaez; J William Harbour
Journal:  Sci Adv       Date:  2022-08-19       Impact factor: 14.957

6.  A decision process for drug discovery in retinoblastoma.

Authors:  María Belen Cancela; Santiago Zugbi; Ursula Winter; Ana Laura Martinez; Claudia Sampor; Mariana Sgroi; Jasmine H Francis; Ralph Garippa; David H Abramson; Guillermo Chantada; Paula Schaiquevich
Journal:  Invest New Drugs       Date:  2020-11-16       Impact factor: 3.850

7.  Molecular Insights on Post-chemotherapy Retinoblastoma by Microarray Gene Expression Analysis.

Authors:  Venkatesan Nalini; Ramya Segu; Perinkulam Ravi Deepa; Vikas Khetan; Madavan Vasudevan; Subramanian Krishnakumar
Journal:  Bioinform Biol Insights       Date:  2013-09-18

8.  Characterization of etoposide- and cisplatin-chemoresistant retinoblastoma cell lines.

Authors:  Maike Busch; David Papior; Harald Stephan; Nicole Dünker
Journal:  Oncol Rep       Date:  2017-11-16       Impact factor: 3.906

Review 9.  Non-Coding RNAs in Retinoblastoma.

Authors:  Meropi Plousiou; Ivan Vannini
Journal:  Front Genet       Date:  2019-11-14       Impact factor: 4.599

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.